Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 63 of 141 for:    MPL

Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02142504
Recruitment Status : Completed
First Posted : May 20, 2014
Results First Posted : February 23, 2017
Last Update Posted : August 21, 2017
Sponsor:
Information provided by (Responsible Party):
Takeda

Brief Summary:
The purpose of this study is to evaluate the safety of the norovirus bivalent virus-like particle (VLP) vaccine for further development by assessing the rates of serious adverse events (SAEs), unsolicited adverse events (AEs), solicited local and solicited systemic AEs, Adverse Events of Special Interest (AESIs) and AEs leading to participant's withdrawal from the trial.

Condition or disease Intervention/treatment Phase
Norovirus Prevention Biological: Norovirus Bivalent VLP Vaccine Drug: Placebo (Saline) Phase 2

Detailed Description:

The vaccine being tested in this study is called norovirus GI.1/GII.4 bivalent virus-like particle (VLP) vaccine adjuvanted with or without monophosphoryl lipid A (MPL) and with aluminum hydroxide. The norovirus vaccine is being tested to provide additional safety and immunogenicity data to enable the vaccine to be further developed. This study will look at the side effects in people who take different formulations of the norovirus vaccine.

The study will enroll approximately 450 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of the 3 treatment groups—which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

  • one dose of GI.1/GII.4 (15 µg/50 µg) adjuvanted with MPL (50 µg) and aluminum hydroxide (500 µg) on Day 1 followed by one dose of GI.1/GII.4 (15 µg/15 µg) adjuvanted with aluminum hydroxide (500 µg) (without MPL) on Day 365
  • one dose of GI.1/GII.4 (50 µg/50 µg) adjuvanted with MPL (50 µg) and aluminum hydroxide (500 µg) on Day 1 followed by one dose of GI.1/GII.4 (15 µg/15 µg) adjuvanted with aluminum hydroxide (500 µg) (without MPL) on Day 365
  • one dose of Saline Placebo (dummy inactive injection) - this is a liquid that has no active ingredient-on Day 1 + GI.1/GII.4 (15 µg/15 µg) adjuvanted with aluminum hydroxide (500 µg) (without MPL) as primary vaccination on Day 365

All participants will be administered vaccine or placebo on Day 1 of the study and will receive a vaccination dose (reduced antigen content) of the norovirus vaccine on Day 365. Participants will be asked to record any symptoms that may be related to the vaccine or the injection site in a diary card for 7 days after each vaccination.

This multi-center trial will be conducted in the United States. The overall time to participate in this study is up to 18 months. Participants will make 11 visits to the clinic including a follow-up visit 6 months after the last dose of study medication.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 454 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Phase II, Randomized, Placebo-controlled, Double-blind, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in Healthy Adults
Actual Study Start Date : May 15, 2014
Actual Primary Completion Date : January 6, 2016
Actual Study Completion Date : January 6, 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL)
Intramuscular (IM) norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminum hydroxide, on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
Biological: Norovirus Bivalent VLP Vaccine
Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with or without MPL and/or aluminum hydroxide IM injection

Experimental: GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL)
IM norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminum hydroxide, on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
Biological: Norovirus Bivalent VLP Vaccine
Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with or without MPL and/or aluminum hydroxide IM injection

Placebo Comparator: Saline Placebo + GI.1/GII.4 15/15 μg (No MPL)
IM saline placebo on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP ) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
Biological: Norovirus Bivalent VLP Vaccine
Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with or without MPL and/or aluminum hydroxide IM injection

Drug: Placebo (Saline)
Placebo-matching norovirus bivalent VLP vaccine




Primary Outcome Measures :
  1. Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the First Injection [ Time Frame: Days 1 through 7 ]
    Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occurred within 7 days after the primary injection.

  2. Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the First Injection [ Time Frame: Days 1 through 7 ]
    Solicited systemic AEs are defined as: headache, fatigue, myalgia, arthralgia, vomiting, and diarrhea that occurred within 7 days after the primary injection.

  3. Percentage of Participants With Elevated Daily Oral Temperature (Fever) After the First Injection [ Time Frame: Days 1 through 7 ]
    Fever is defined as greater than or equal to 38°C (100.4°F). Oral body temperature measurement was performed using the thermometer provided by the site for 7 days after each injection. The highest body temperature observed each day was recorded on the Diary Card also provided by the site.

  4. Percentage of Participants With Unsolicited Adverse Events (AEs) After the First Injection [ Time Frame: Days 1 through 28 ]
    Unsolicited AEs are any AEs that are not solicited local or systemic AEs, as defined by this study.

  5. Percentage of Participants With Serious Adverse Events (SAEs) After the First Injection [ Time Frame: From first injection (Day 1) to second injection pre-dose (Up to Day 365) ]
    A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.

  6. Percentage of Participants With Serious Adverse Events (SAEs) After the Second Injection [ Time Frame: From second injection (Day 365) to 6 months after second injection (Up to Day 545) ]
    A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.

  7. Percentage of Participants With Adverse Events of Special Interest (AESI) After the First Injection [ Time Frame: From first injection (Day 1) to second injection pre-dose (Up to Day 365) ]
    AESIs are AEs that are not solicited local or systemic AEs, they are predefined AEs that required close monitoring and prompt reporting to the sponsor. AESI included protocol specified Cardiac Disorders, Gastrointestinal Disorders, Immune System Disorders, Infections and Infestations, Musculoskeletal and Connective Tissue Diseases, Neuroinflammatory Disorders, Renal and Urinary Disorders, Skin Disorders, Thyroid Disorders, Vascular Disorders and Other Disorders.

  8. Percentage of Participants With Adverse Events of Special Interest (AESI) After the Second Injection [ Time Frame: From second injection (Day 365) to 6 months after second injection (Up to Day 545) ]
    AESIs are AEs that are not solicited local or systemic AEs, they are predefined AEs that required close monitoring and prompt reporting to the sponsor. AESI included protocol specified Cardiac Disorders, Gastrointestinal Disorders, Immune System Disorders, Infections and Infestations, Musculoskeletal and Connective Tissue Diseases, Neuroinflammatory Disorders, Renal and Urinary Disorders, Skin Disorders, Thyroid Disorders, Vascular Disorders and Other Disorders.

  9. Percentage of Participants With Any Adverse Event (AE) Leading to Withdrawal From the Study [ Time Frame: Unsolicited AEs 28 days after each injection (Days 1 to 28 and Days 365 to 393), and Serious Adverse Events (SAEs) throughout the trial (Up to Day 545) ]
    Withdrawal due to an AE occurred if the participant experienced an AE that required early termination because continued participation imposed an unacceptable risk to the participant's health or the participant was unwilling to continue because of the AE.


Secondary Outcome Measures :
  1. Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the Second Injection [ Time Frame: Days 365 through 371 ]
    Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occurred within 7 days after the vaccination on Day 365.

  2. Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the Second Injection [ Time Frame: Days 365 through 371 ]
    Solicited systemic AEs are defined as: headache, fatigue, myalgia, arthralgia, vomiting, and diarrhea that occurred within 7 days after the vaccination on Day 365.

  3. Percentage of Participants With Elevated Daily Oral Temperature (Fever) After the Second Injection [ Time Frame: Days 365 through 371 ]
    Fever is defined as greater than or equal to 38°C (100.4°F). Oral body temperature measurement was performed using the thermometer provided by the site for 7 days after each vaccination. The highest body temperature observed each day was recorded on the Diary Card also provided by the site.

  4. Percentage of Participants With Unsolicited Adverse Events (AEs) After the Second Injection [ Time Frame: Days 365 through 393 ]
    Unsolicited AEs are any AEs that are not solicited local or systemic AEs, as defined by this study.

  5. Percentage of Participants With a Seroresponse in Both Serum Anti-norovirus GI.1 VLP and GII.4 VLP (Pan-Ig ELISA) [ Time Frame: Baseline and Day 28 ]
    Seroresponse is defined as 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 virus-Like particle (VLP) and GII.4 VLP as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).

  6. Percentage of Participants With a Seroresponse in Serum Anti-norovirus GI.1 VLP (Pan-Ig ELISA) [ Time Frame: Baseline and Day 28 ]
    Seroresponse is defined as 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-Like particle (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).

  7. Percentage of Participants With a Seroresponse in Serum Anti-norovirus GII.4 VLP (Pan-Ig ELISA) [ Time Frame: Baseline and Day 28 ]
    Seroresponse is defined as 4-fold rise or greater in serum anti-norovirus antibody titers for GII.4 virus-like particles (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).

  8. Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (Pan-Ig ELISA) [ Time Frame: Day 28 ]
    Geometric mean titer (GMT) of anti-norovirus GI.1 VLP antibody titers as measured by Pan-Ig ELISA.

  9. Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (Pan-Ig ELISA) [ Time Frame: Day 28 ]
    Geometric mean titer (GMT) of anti-norovirus GII.4 VLP antibody titers as measured by Pan-Ig ELISA.

  10. Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (Pan-Ig ELISA) [ Time Frame: Day 28 ]
    Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by Pan-Ig ELISA.

  11. Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (Pan-Ig ELISA) [ Time Frame: Day 28 ]
    Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by Pan-Ig ELISA.

  12. Percentage of Participants With a Seroresponse in Both Serum Anti-norovirus GI.1 VLP and GII.4 VLP (HBGA) [ Time Frame: Baseline and Day 28 ]
    Seroresponse is defined as 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 virus-Like particle (VLP) and GII.4 VLP as measured by histoblood group antigen (HBGA) binding assay.

  13. Percentage of Participants With a Seroresponse in Serum GI.1 VLP Antibody Titers (HBGA) [ Time Frame: Baseline and Day 28 ]
    Seroresponse is defined as 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-Like particle (VLP) as measured by HBGA binding assay.

  14. Percentage of Participants With a Seroresponse in Serum GII.4 VLP Antibody Titers (HBGA) [ Time Frame: Baseline and Day 28 ]
    Seroresponse is defined as 4-fold rise or greater in serum anti-norovirus antibody titers for GII.4 virus-Like particle (VLP) as measured by HBGA binding assay.

  15. Blocking Titers 50 (BT50) of Anti-Norovirus GI.1 VLP Antibody Titers (HBGA) [ Time Frame: Day 28 ]
    Blocking titers 50 (BT50) of anti-norovirus GI.1 VLP antibody titers as measured by HBGA binding assay.

  16. Blocking Titers 50 (BT50) of Anti-Norovirus GII.4 VLP Antibody Titers (HBGA) [ Time Frame: Day 28 ]
    Blocking titers 50 (BT50) of anti-norovirus GII.4 VLP antibody titers as measured by HBGA binding assay.

  17. Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (HBGA) [ Time Frame: Day 28 ]
    Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by HBGA binding assay.

  18. Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (HBGA) [ Time Frame: Day 28 ]
    Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by the HBGA binding assay.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 49 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male and female participants aged 18 to 49 years of age at the time of enrollment.
  2. Are in good health at the time of entry into the trial as determined by medical history, physical examination and clinical judgment of the investigator.
  3. Participants with a signed informed consent form and any required privacy authorization prior to the initiation of any trial procedures and after the nature of the trial has been explained according to local regulatory requirements.
  4. Can comply with trial procedures and are available for the duration of the trial.

Exclusion Criteria:

  1. Has a history of acute gastroenteritis within 14 days of enrollment.
  2. Has a clinically significant active infection (as assessed by the investigator) or oral body temperature 38°C (100.4°F) or higher within 3 days of the intended date of vaccination.
  3. Has received antipyretic/analgesic medications within 24 hours prior to the intended vaccine administration.
  4. Has known hypersensitivity or allergy to any of the bivalent norovirus virus-like particle (VLP) vaccine components (including excipients of the investigational vaccines).
  5. Has behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the participant's ability to participate in the trial.
  6. Has a history of any progressive or severe neurologic disorder, seizure disorder, or neuro-inflammatory disease (e.g., Guillain-Barré syndrome).
  7. Has history or any illness that, in the opinion of the investigator, might interfere with the results of the trial or pose additional risk to the participants due to participation in the trial.
  8. Has known or suspected impairment/alteration of immune function including the following:

    1. Chronic use of oral steroids (Equivalent to 20 mg/day prednisone for ≥ 12 weeks / ≥2 mg/kg body weight /day for ≥ 2 weeks) within 60 days prior to Day 1 (use of inhaled, intranasal, or topical corticosteroids is allowed).
    2. Receipt of parenteral steroids (equivalent to 20 mg/day prednisone ≥ 12 weeks / ≥2 mg/kg body weight /day for ≥2 weeks) within 60 days prior to Day 1.
    3. Receipt of immunostimulants within 60 days prior to Day 1.
    4. Receipt of parenteral, epidural, or intra-articular immunoglobulin preparation, blood products, and/or plasma derivatives within 3 months prior to Day 1 or planned during the full length of the trial.
    5. Receipt of immunosuppressive therapy within 6 months prior to Day 1.
    6. Human immunodeficiency virus (HIV) infection or HIV-related disease.
    7. Heritable immunodeficiency.
  9. Has abnormalities of splenic or thymic function.
  10. Has a history of any autoimmune disease.
  11. Has a known bleeding diathesis or any condition that may be associated with a prolonged bleeding time.
  12. Has any serious chronic or progressive disease according to judgment of the investigator (e.g., neoplasm, insulin dependent diabetes, cardiac, renal, or hepatic disease).
  13. Has a body mass index (BMI) greater than or equal to 35 kg/m^2 (= weight in kg / [height in meters * height in meters]).
  14. Is participating in any clinical trial with another investigational product 30 days prior to first trial visit or intent to participate in another clinical trial at any time during the conduct of this trial.
  15. Participants who received any inactivated vaccines within 14 days or any live vaccines for 28 days prior to enrollment in this trial.
  16. Are first degree relatives of individuals involved in trial conduct.
  17. Has a history of substance or alcohol abuse within the past 2 years.
  18. If female, "of childbearing potential", sexually active, and has not used any of the "acceptable contraceptive methods" for at least 2 months prior to trial entry:

    1. Of childbearing potential is defined as status post onset of menarche and not meeting any of the following conditions: menopausal for at least 2 years, status after bilateral tubal ligation for at least 1 year, status after bilateral oophorectomy, or status after hysterectomy.
    2. Acceptable birth control methods are defined as 1 or more of the following:

    i. Hormonal contraceptive (such as oral, injection, transdermal patch, implant, cervical ring).

    ii. Barrier (condom with spermicide or diaphragm with spermicide) each and every time during intercourse.

    iii. Intrauterine device (IUD). iv. Monogamous relationship with vasectomized partner. Partner must have been vasectomized for at least 6 months prior to the participant's trial entry.

  19. Female participants of childbearing potential and sexually active, who refuse to use an "acceptable contraceptive method" from Day 1 through 6 months after the last dose of investigational vaccine.
  20. Female participants who plan to donate ova from Day 1 through 6 months after the last dose of investigational vaccine.
  21. Female participants with any positive pregnancy test.
  22. Female participants who are pregnant or breastfeeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02142504


Locations
Layout table for location information
United States, California
California Research Foundation
San Diego, California, United States, 92103-6204
Benchmark Research San Francisco
San Francisco, California, United States, 94108
United States, Florida
Clin Research of South Florida
Coral Gables, Florida, United States, 33134
United States, Maryland
SNBL
Baltimore, Maryland, United States, 21201
United States, Missouri
St. Louis University, School of Medicine
Saint Louis, Missouri, United States, 63104
United States, New York
Rochester Clinical Research
Rochester, New York, United States, 14609
University of Rochester
Rochester, New York, United States, 14642
United States, Ohio
Cincinnati Childrens Hospital Medical Center
Cincinnati, Ohio, United States, 45206
United States, Texas
Benchmark Research Austin
Austin, Texas, United States, 78705
Baylor College of Medicine
Houston, Texas, United States, 77030-3498
Sponsors and Collaborators
Takeda
Investigators
Layout table for investigator information
Study Director: Medical Director Clinical Science Takeda

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT02142504     History of Changes
Other Study ID Numbers: NOR-201
U1111-1155-8803 ( Other Identifier: World Health Organization )
First Posted: May 20, 2014    Key Record Dates
Results First Posted: February 23, 2017
Last Update Posted: August 21, 2017
Last Verified: August 2017

Keywords provided by Takeda:
Drug therapy

Additional relevant MeSH terms:
Layout table for MeSH terms
Aluminum Hydroxide
Vaccines
Monophosphoryl lipid A
Immunologic Factors
Physiological Effects of Drugs
Adjuvants, Immunologic
Antacids
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents